By Application
Hot products 
-
Mouse Anti-CD46 Recombinant Antibody (CBFYC-0076) (CBMAB-C0085-FY)
-
Mouse Anti-DMPK Recombinant Antibody (CBYCD-324) (CBMAB-D1200-YC)
-
Rat Anti-ADAM10 Recombinant Antibody (V2-179741) (CBMAB-A1103-YC)
-
Mouse Anti-AAV-5 Recombinant Antibody (V2-503416) (CBMAB-V208-1402-FY)
-
Mouse Anti-ALB Recombinant Antibody (V2-180650) (CBMAB-A2186-YC)
-
Mouse Anti-BANF1 Recombinant Antibody (3F10-4G12) (CBMAB-A0707-LY)
-
Rat Anti-CD34 Recombinant Antibody (MEC 14.7) (CBMAB-C10196-LY)
-
Mouse Anti-CD164 Recombinant Antibody (CBFYC-0077) (CBMAB-C0086-FY)
-
Mouse Anti-BHMT Recombinant Antibody (CBYY-0547) (CBMAB-0550-YY)
-
Mouse Anti-CHRNA9 Recombinant Antibody (8E4) (CBMAB-C9161-LY)
-
Mouse Anti-CFL1 (Phospho-Ser3) Recombinant Antibody (CBFYC-1770) (CBMAB-C1832-FY)
-
Rat Anti-4-1BB Recombinant Antibody (V2-1558) (CBMAB-0953-LY)
-
Mouse Anti-CAPZB Recombinant Antibody (CBYY-C0944) (CBMAB-C2381-YY)
-
Mouse Anti-CCS Recombinant Antibody (CBFYC-1093) (CBMAB-C1150-FY)
-
Mouse Anti-A2M Recombinant Antibody (V2-178822) (CBMAB-A0036-YC)
-
Mouse Anti-ALPL Antibody (B4-78) (CBMAB-1009CQ)
-
Mouse Anti-CD24 Recombinant Antibody (2Q1282) (CBMAB-C1624-CN)
-
Mouse Anti-APP Recombinant Antibody (5C2A1) (CBMAB-A3314-YC)
-
Mouse Anti-ADGRE2 Recombinant Antibody (V2-261270) (CBMAB-C0813-LY)
-
Mouse Anti-CCT6A/B Recombinant Antibody (CBXC-0168) (CBMAB-C5570-CQ)
Cervical Cancer
Fig.1 Cervical cancer
Cervical cancer is a cancer originated from the cervix. Globally, cervical cancer is the fourth-most common cause of death from cancer among women and fourth-most common cause of cancer. At early stage, typically no symptoms are been found. However, later symptoms may include pelvic pain, vaginal bleeding, or pain during sexual intercourse. While bleeding after sex may not to be treated seriously, it may also reveal the presence of cervical cancer. Human papillomavirus (HPV) infection leads to about 90% of cases, followed by smoking. However, majority of people who have had HPV infections, do not develop cervical cancer. Cervical cancer typically develops from precancerous changes for 10 to 20 years. Around 90% of cervical cancer cases are diagnosed as squamous cell carcinomas, 10% are adenocarcinoma, and a small number are other types. Some novel prognostic markers, like TBLR1, MicroRNA-497, have been studied recently.
Loading...
Compare
